GSK plc (GLAXF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director | 6.71M | 67.14M | 1969 |
| Ms. Julie Belita Brown | CFO & Executive Director | 6.41M | -- | 1962 |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | -- | -- | 1971 |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | -- | -- | -- |
| Ms. Sarah Elton-Farr | Head of Investor Relations | -- | -- | -- |
| Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance | -- | -- | -- |
| Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office | -- | -- | -- |
| Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development | -- | -- | 1966 |
| Ms. Diana Conrad | Chief People Officer | -- | -- | -- |
| Mr. Philip C. Thomson | President of Global Affairs | -- | -- | -- |
GSK plc
- Sector:
- Healthcare
- Industry: Drug Manufacturers - General
- Full Time Employees:
- 70,212
Description
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Corporate Governance
Recent Events
- Feb 22, 2024Ex-Dividend Date
- Oct 10, 2019Dividend Date
Upcoming Events
Upcoming Events Information Not Available